Abstract：
BACKGROUND:Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC. MATERIALS AND METHODS:All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Norway (N = 1548), with information on age, gender, stage, county of residence, radiotherapy, and survival. RESULTS:Median age was 66 years; 71% were females. World age-standardized incidence rates increased (1987-2016) from 0.79 (95% confidence interval [CI], 0.69-0.90) to 1.10 (95% CI, 1.00-1.22) per 100,000 person-years in females and, from 0.34 (95% CI, 0.28-0.42) to 0.47 (95% CI, 0.40-0.54) in males. Estimated annual percentage change was 1.7 (95% CI, 0.9-2.6) for females and 1.3 (95% CI, -0.1 to 2.7) for males. Incidence rates increased with age; the relative risk was higher in major cities. Five-year net survival increased from 63.4% to 72.7% (1987-2016), but for age ≥ 70 years remained ∼57%. Net survival was dependant on stage, age, and gender. Five-year net survival (1997-2016) was 76.4% after curative radiotherapy, and 18.0% after palliative radiotherapy. CONCLUSION:ASCC incidence rates increased from 1987 to 2016, and survival improved for patients < 70 years. Five-year net survival was 76% after curative radiotherapy in Norway.
journal_name
Clin Colorectal Cancerjournal_title
Clinical colorectal cancerauthors
Guren MG,Aagnes B,Nygård M,Dahl O,Møller Bdoi
10.1016/j.clcc.2018.10.001subject
Has Abstractpub_date
2019-03-01 00:00:00pages
e96-e103issue
1eissn
1533-0028issn
1938-0674pii
S1533-0028(18)30300-1journal_volume
18pub_type
杂志文章abstract：BACKGROUND:New treatment modalities and a growing understanding of the complex genetic tumor landscape have improved the outcome of colorectal cancer (CRC) patients. Nonetheless, more individualized treatment regimens, taking individual tumor characteristics into account, have been recently postulated and prognostic bi...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.02.008
更新日期：2018-06-01 00:00:00
abstract：BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2020.05.011
更新日期：2020-09-01 00:00:00
abstract：:Regimens based on flouropyrimidines (eg, 5-fluorouracil [5-FU] and capecitabine) are the mainstay of chemotherapy for several malignancies, including colon, pancreatic, upper gastrointestinal, and breast cancers. Warfarin is one of the most commonly used oral anticoagulants. Patients receiving concomitant capecitabine...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/ccc.2005.n.028
更新日期：2005-09-01 00:00:00
abstract：BACKGROUND:Treatment sequencing for patients with refractory metastatic colorectal cancer (mCRC) has been highly debated. The thymidine-based nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib have demonstrated clinical benefits in randomized phase III trials compared with placebo. Ho...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.05.012
更新日期：2018-12-01 00:00:00
abstract：INTRODUCTION:Hepatic arterial infusion chemotherapy (HAIC) is a treatment used for liver metastases (LM) of colorectal cancer (CRC). Because of its technical conditions, it has been used in only a few experienced centers in France. Our aim was to evaluate its feasibility, efficacy and tolerance in 4 centers. METHODS:C...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clcc.2017.03.003
更新日期：2017-12-01 00:00:00
abstract：:Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States. Despite excellent prognosis for early stage disease, 5-year survival rates in metastatic disease remain low. A small subset of CRC is defined by a deficiency in mismatch repair (dMMR) resulting in high levels of micro...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clcc.2020.02.002
更新日期：2020-06-01 00:00:00
abstract：BACKGROUND:The optimal therapeutic strategy for metastatic colorectal cancer patients is still a matter of debate. There are no prognostic variables indicating how many lines individual patients ought to receive, and whether later lines could be effective even when earlier ones were not. PATIENTS AND METHODS:We retros...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2017.03.019
更新日期：2017-12-01 00:00:00
abstract：BACKGROUND:Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. PATIENTS AND METHODS:Using a modified Simon accelerated titration design, adults with...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2020.08.003
更新日期：2020-08-19 00:00:00
abstract：:Despite an armamentarium that is wide in range, scope of action, and target, chemotherapy has limited success in colorectal cancer (CRC). Novel approaches are needed to overcome tumor barriers to chemotherapy that includes an abnormal tumor vasculature constituting a poor drug delivery system. We have previously shown...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2009.n.025
更新日期：2009-07-01 00:00:00
abstract：:The development of brain metastases originating from colorectal cancer (CRC) is an infrequent phenomenon occurring in < 5% of patients. Yet, it is feasible that physicians will be diagnosing more patients with brain metastases because of the prolonged survival in our current patient population. The anti-angiogenic age...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2008.n.010
更新日期：2008-01-01 00:00:00
abstract：INTRODUCTION:The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In this double-blinded, phase II trial, patients with mCRC who had not progressed after 6...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.clcc.2018.02.004
更新日期：2018-06-01 00:00:00
abstract：BACKGROUND:ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2020.06.009
更新日期：2020-12-01 00:00:00
abstract：:Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise infusional 5-fluorouracil (5-FU), leucovorin, and irinotecan or oxaliplatin. The fluoropyrimidine derivative capecitabine is at least as effective as 5-FU plus leucovorin bolus regimens. It displays a favorable toxicity profile and offer...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/CCC.2008.n.015
更新日期：2008-03-01 00:00:00
abstract：BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-r...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.08.002
更新日期：2018-12-01 00:00:00
abstract：:Primary squamous cell colorectal carcinomas are uncommon, and their characteristics are not well known. They seem to occur most commonly in the fifth decade of life with a slight predominance for men. The most commonly reported anatomic locations are the rectum and the proximal colon. Clinical features and common diag...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2001.n.006
更新日期：2001-05-01 00:00:00
abstract：:Hepatic colorectal metastases present a challenging problem in patients with recurrent colorectal cancer. Twenty percent of patients with recurrence will have liver metastases as a component of their disease, and only 10% of these patients will have isolated liver metastases that are resectable. Although systemic chem...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/CCC.2003.n.010
更新日期：2003-05-01 00:00:00
abstract：:Combination protocols of 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan or oxaliplatin have demonstrated high activity in metastatic colorectal cancer. Capecitabine, an oral 5-FU prodrug, may replace infusional 5-FU/LV in combination protocols with irinotecan or oxaliplatin. We therefore initiated a phase II stud...
journal_title：Clinical colorectal cancer
pub_type： 临床试验,杂志文章
doi：10.3816/ccc.2004.n.009
更新日期：2004-05-01 00:00:00
abstract：BACKGROUND:Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS:The Harris Health System (HHS) is an integrated health delivery network that provides medical car...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2019.09.002
更新日期：2020-06-01 00:00:00
abstract：BACKGROUND:Few patients with metastatic colorectal cancer (mCRC) are candidates for resection of their hepatic disease. Yttrium-90 ((90)Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent (90)Y r...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2011.12.002
更新日期：2012-09-01 00:00:00
abstract：:Local excision is an alternative approach to radical proctectomy for rectal cancer, but from an oncologic standpoint, it is a compromise, and its role remains controversial. Careful patient selection is essential because local excision is generally considered only for early rectal cancer with no evidence of nodal meta...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/CCC.2008.n.050
更新日期：2008-11-01 00:00:00
abstract：:Thymidylate synthase (TS) is a key enzyme in the synthesis of 2'-deoxythymidine-5'-monophosphate, an essential precursor for DNA biosynthesis. For this reason, this enzyme is a critical target in cancer chemotherapy. As the first TS inhibitor in clinical use, 5-fluorouracil (5-FU) remains widely used for the treatment...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/CCC.2002.n.003
更新日期：2002-02-01 00:00:00
abstract：BACKGROUND:Köhne prognostic score is used to classify patients with metastatic colorectal cancer (mCRC) as high, intermediate, or low risk. Using data from 2 phase III trials, we analyzed survival in patients categorized according to Köhne prognostic category and virus-induced rapidly accelerated fibrosarcoma murine sa...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2017.09.006
更新日期：2018-03-01 00:00:00
abstract：:Vascular endothelial growth factor (VEGF) is the driving force behind angiogenesis in most solid malignancies. This also holds true for colorectal cancer (CRC), where increased levels of VEGF in primary cancers are associated with increased microvessel density and poor prognosis. These findings have led to preclinical...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/ccc.2004.s.009
更新日期：2004-10-01 00:00:00
abstract：:This article reviews the current status of the topoisomerase I (top I) inhibitors in the treatment of gastrointestinal (GI) malignancies. We focus on oral drug administration, the mode of administration that is generally preferred by patients with cancer. However, the great majority of the studies have been performed ...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/ccc.2004.n.017
更新日期：2004-09-01 00:00:00
abstract：BACKGROUND:The safety of bevacizumab in older mCRC patients is poorly understood. The purpose of this analysis was to determine the prevalence, incidence, and risk factors for treatment-related AEs in older bevacizumab recipients. PATIENTS AND METHODS:Patients age ≥65 were identified from SEER-Medicare and categorized...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2012.11.004
更新日期：2013-09-01 00:00:00
abstract：BACKGROUND:No biomarkers exist to predict benefit from antiangiogenic therapy in metastatic colorectal cancer patients. ACVRL1 (activin receptor like-protein 1) encodes for ALK1, a member of the transforming growth factor-β receptor family, which directs pathologic angiogenesis. We examined the intratumoral expression ...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.03.006
更新日期：2018-09-01 00:00:00
abstract：:Adult intussusception is a rare occurrence and, unlike in childhood, is usually associated with an underlying tumor. Although computed tomography (CT) imaging can identify an intussusception and point toward a cause, diagnosis is challenging if it is only intermittent. When an intussusception presents in the context o...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2008.n.028
更新日期：2008-05-01 00:00:00
abstract：BACKGROUND:Colorectal cancer (CRC) is a common malignancy. There is growing evidence that CRC incidence is increasing in the younger population. There is controversy surrounding the prognosis of young patients with CRC. In this study we reviewed Australian patients with metastatic CRC (mCRC) who were younger than 40 ye...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2015.07.005
更新日期：2016-03-01 00:00:00
abstract：:The multiplicity of chemotherapy regimens currently available to treat colorectal cancer in the first-line setting precludes the identification of a single standard regimen for front-line therapy. The previous standard, 5-fluorouracil (5-FU), formerly the only agent with any significant activity against colorectal can...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/ccc.2004.s.002
更新日期：2004-06-01 00:00:00
abstract：BACKGROUND:The prognostic value of tumor sidedness in metastatic colorectal cancer (CRC) has been established, but its impact on nonmetastatic disease remains unclear. Our study aimed to explore the prognostic effect of tumor sidedness by subgroup survival analyses, according to histology and tumor grade in stage I-IV ...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.10.005
更新日期：2019-03-01 00:00:00
